Dora Lai-Wan Kwong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9746854/publications.pdf

Version: 2024-02-01

48 papers 1,349 citations

394421 19 h-index 35 g-index

48 all docs

48 docs citations

48 times ranked

1900 citing authors

#	Article	IF	Citations
1	Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma. Angiogenesis, 2022, 25, 181-203.	7.2	15
2	Refining TNM-8ÂM1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncology, 2022, 126, 105736.	1.5	4
3	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2022, 28, 2679-2689.	7.0	4
4	An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma. Cancers, 2022, 14, 1923.	3.7	1
5	MAEL Augments Cancer Stemness Properties and Resistance to Sorafenib in Hepatocellular Carcinoma through the PTGS2/AKT/STAT3 Axis. Cancers, 2022, 14, 2880.	3.7	7
6	SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes. Cancers, 2022, 14, 3285.	3.7	11
7	Incidence and Demographics of Nasopharyngeal Carcinoma in Cheung Chau Island of Hong Kong—A Distinct Geographical Area With Minimal Residential Mobility and Restricted Public Healthcare Referral Network. Cancer Control, 2021, 28, 107327482110471.	1.8	2
8	The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 626145.	2.8	9
9	Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. Oral Oncology, 2021, 114, 105158.	1.5	7
10	Computer-assisted ultrasound assessment of plaque characteristics in radiation-induced and non-radiation-induced carotid atherosclerosis. Quantitative Imaging in Medicine and Surgery, 2021, 11, 2292-2306.	2.0	5
11	Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers, 2021, 13, 3797.	3.7	2
12	Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence from a multicenter case–control study. Clinical Nutrition, 2021, 40, 5180-5188.	5.0	1
13	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 744889.	2.8	19
14	Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report. BMC Infectious Diseases, 2021, 21, 1148.	2.9	5
15	FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma. Theranostics, 2020, 10, 11535-11548.	10.0	72
16	Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 1937-1947.	1.7	12
17	Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy. Frontiers in Oncology, 2020, 10, 1417.	2.8	11
18	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. Communications Biology, 2020, 3, 759.	4.4	17

#	Article	IF	CITATIONS
19	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. British Journal of Cancer, 2020, 123, 114-125.	6.4	14
20	Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma. Cancers, 2020, 12, 1352.	3.7	13
21	Saliva electrolyte analysis and xerostomia-related quality of life in nasopharyngeal carcinoma patients following intensity-modulated radiation therapy. Radiotherapy and Oncology, 2020, 150, 97-103.	0.6	22
22	Outcome of Chinese children with craniopharyngioma: a 20-year population-based study by the Hong Kong Pediatric Hematology/Oncology Study Group. Child's Nervous System, 2020, 36, 497-505.	1.1	12
23	<i>CHL1</i> suppresses tumor growth and metastasis in nasopharyngeal carcinoma by repressing PI3K/AKT signaling pathway via interaction with Integrin \hat{I}^21 and Merlin. International Journal of Biological Sciences, 2019, 15, 1802-1815.	6.4	18
24	Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. British Journal of Cancer, 2019, 121, 690-698.	6.4	19
25	The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. International Journal of Cancer, 2019, 144, 1713-1722.	5.1	82
26	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nature Communications, 2018, 9, 4663.	12.8	106
27	Evaluation of circulating EBV microRNA BART2â€5p in facilitating early detection and screening of nasopharyngeal carcinoma. International Journal of Cancer, 2018, 143, 3209-3217.	5.1	43
28	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in <scp>H</scp> ong <scp>K</scp> ong <scp>C</scp> hinese. International Journal of Cancer, 2018, 143, 2289-2298.	5.1	9
29	Impact of intravenous contrast used in computed tomography on radiation dose to carotid arteries and thyroid in intensity-modulated radiation therapy planning for nasopharyngeal carcinoma. Medical Dosimetry, 2017, 42, 137-144.	0.9	0
30	Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 116, 68-81.	4.4	30
31	Calciumâ€binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signalâ€regulated kinase signaling pathway. Hepatology, 2017, 66, 1529-1545.	7.3	52
32	Cervical nodal volume for prognostication and risk stratification of patients with nasopharyngeal carcinoma, and implications on the TNM-staging system. Scientific Reports, 2017, 7, 10387.	3.3	24
33	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Regional Nodal Metastasis in Nasopharyngeal Carcinoma: Correlation with Nodal Staging. Contrast Media and Molecular Imaging, 2017, 2017, 1-6.	0.8	6
34	AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-ÎB signaling pathways. Oncotarget, 2017, 8, 83469-83479.	1.8	24
35	Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget, 2017, 8, 5292-5308.	1.8	39
36	Whole-exome sequencing identifies multiple loss-of-function mutations of NF- \hat{l}^2 B pathway regulators in nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11283-11288.	7.1	144

#	Article	IF	CITATIONS
37	Whole-exome sequencing identifies $\langle i\rangle$ MST1R $\langle i\rangle$ as a genetic susceptibility gene in nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3317-3322.	7.1	71
38	Metastasis-suppressing <i>NID2</i> , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 78859-78871.	1.8	33
39	NF- \hat{l}^2 B p65 Subunit Is Modulated by Latent Transforming Growth Factor- \hat{l}^2 Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. PLoS ONE, 2015, 10, e0127239.	2.5	29
40	Effects of Calcium Phosphate Nanocrystals on Osseointegration of Titanium Implant in Irradiated Bone. BioMed Research International, 2015, 2015, 1-6.	1.9	5
41	Effect of Fluoride-Modified Titanium Surface on Early Adhesion of Irradiated Osteoblasts. BioMed Research International, 2015, 2015, 1-9.	1.9	4
42	Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylationâ€sensitive high resolution melting. International Journal of Cancer, 2015, 136, E127-35.	5.1	72
43	Association of XRCC1 and XRCC3 gene haplotypes with the development of radiation-induced fibrosis in patients with nasopharyngeal carcinoma. Molecular and Clinical Oncology, 2014, 2, 553-558.	1.0	19
44	Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiology, 2013, 37, 708-713.	1.9	50
45	Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, e14530-e14530.	1.6	O
46	Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer, 2006, 107, 99-107.	4.1	37
47	Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma. Clinical Cancer Research, 2004, 10, 2401-2406.	7. 0	101
48	Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. International Journal of Cancer, 2003, 105, 851-855.	5.1	67